Ratio Therapeutics Inc., a US-based pharmaceutical company that said it is focused on developing innovative radiopharmaceuticals for the treatment of cancer, announced on Tuesday that it has opened its new headquarters and R&D facility in the Innovation and Design Building located in Boston's Seaport District.

The facility covers 19,000-square-foot area and Ratio said that it will continue to recruit biologists, chemists and data scientists to join its team of experts focused on the development of novel radiotherapeutics.

Dr Jack Hoppin, Ratio's chairman and CEO, said, 'We are excited about opening Ratio's state-of-the-art facility that will enable us to accelerate the development of our proprietary platforms to bring novel radiopharmaceuticals to patients in need. The new headquarters will house biochemistry, medicinal chemistry, radiochemistry and biology labs, as well as office spaces that can accommodate up to 65 total personnel. Ratio has hired 10 new teammates this year and we will continue to grow the team as we expand our efforts.'